Search Within

Sarcoma Service

Formats
  1. Journal Article (455)
  2. Meeting Abstract (431)
  3. Review (29)
  4. Editorial (9)
  5. Guidelines (8)
  6. Book Section (6)
  7. Miscellaneous (6)
  8. Research Letter (6)
  9. Correspondence (2)
  10. Book Whole (1)
Groups
  1. Department of Medicine (953)
  2. Solid Tumor Oncology Division (953)
  3. GSK Faculty (343)
  4. Tow Center for Developmental Oncology (TCDO) (310)
  5. Hematologic Malignancies, Division of (295)
  6. Department of Pathology and Laboratory Medicine (241)

More Groups

People
  1. William Tap (382)
  2. Sandra D'Angelo (256)
  3. Mrinal Gounder (232)
  4. Ping Chi (177)
  5. Mark Dickson (173)
  6. Cristina Antonescu (138)

More People

Years
  1. 2025 (44)
  2. 2024 (87)
  3. 2023 (79)
  4. 2022 (116)
  5. 2021 (76)
  6. 2020 (90)

More Years

Publications
  1. Journal of Clinical Oncology (274)
  2. Annals of Oncology (70)
  3. Clinical Cancer Research (61)
  4. Cancer Research (31)
  5. Journal for ImmunoTherapy of Cancer (28)
  6. Cancer (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (288)
  2. American Association for Cancer Research (108)
  3. Oxford University Press (92)
  4. Elsevier Inc. (57)
  5. Nature Publishing Group (42)
  6. Springer (40)

More Publishers

Results (953)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Presence of immune infiltrates, increased expression of transposable elements, and viral response pathways in sarcoma associate with response to checkpoint inhibition
    Meeting Abstract

    Nacev, B. A.; Bradic, M.; Richards, A. L.; Kelly, C. M.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Chi, P.; Movva, S.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Surufatinib in US patients with soft tissue sarcoma
    Meeting Abstract

    Movva, S.; Spira, A. I.; Hamilton, E. P.; Wang, J. S.; Cohn, A. L.; Strauss, J. F.; Stacchiotti, S.; Tucci, C.; Kauh, J.; Nanda, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The emerging fifth epidemiologic subtype of Kaposi sarcoma in HIV-negative men who have sex with men at a tertiary care center in NYC from 2000 to 2021
    Meeting Abstract

    Morales, A. E.; Benson, G.; Glavan, S.; Giuliano, R.; Dickson, M. A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors
    Meeting Abstract

    McKean, M.; Tolcher, A. W.; Reeves, J. A.; Chmielowski, B.; Shaheen, M. F.; Beck, J. T.; Orloff, M. M.; Somaiah, N.; Van Tine, B. A.; Drabick, J. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma
    Meeting Abstract

    Kinnaman, M. D.; Zaccaria, S.; Makohon-Moore, A.; Gundem, G.; Ossa, J. E. A.; Bouvier, N.; Dela Cruz, F. S.; Hameed, M.; Bender, J. L. G.; Tap, W. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)
    Meeting Abstract

    Gounder, M. M.; Yamamoto, N.; Patel, M. R.; Bauer, T. M.; Schöffski, P.; Grempler, R.; Durland-Busbice, S.; Geng, J.; Maerten, A.; LoRusso, P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas
    Meeting Abstract

    Gounder, M. M.; Schwartz, G. K.; Jones, R. L.; Chawla, S. P.; Chua-Alcala, V. S.; Stacchiotti, S.; Wagner, A. J.; Cote, G. M.; Maki, R. G.; Kosela-Paterczyk, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)
    Meeting Abstract

    Dumbrava, E. E.; Hanna, G. J.; Cote, G. M.; Stinchcombe, T.; Johnson, M. L.; Chen, C.; Devarakonda, S.; Shah, N.; Xu, F.; Doebele, R. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
    Meeting Abstract

    Dickson, M. A.; Ravi, V.; Riedel, R. F.; Ganjoo, K. N.; Van Tine, B. A.; Chugh, R.; Cranmer, L. D.; Gordon, E. M.; Chen, J. L.; Murphy, M. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save